Esophageal Cancer

Brunner, Thomas; Rupp, Andreas; Melzner, W.; Grabenbauer, Gerhard G.; Sauer, Rolf

doi:10.1007/s00066-008-1787-5

Cited by 19 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mentioned trials were conducted prior to the era of IMRT and IGBT. The trial results were confirmed through an additional prospective trial from Brunner et [ 77 ]. Current BT trials for ECa are focusing on palliation.…”

Section: Discussionmentioning

confidence: 70%

Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database

et al. 2016

View full text Add to dashboard Cite

BackgroundTo evaluate the current status of prospective interventional clinical trials that includes brachytherapy (BT) procedures.MethodsThe records of 175,538 (100 %) clinical trials registered at ClinicalTrials.gov were downloaded on September 2014 and a database was established. Trials using BT as an intervention were identified for further analyses. The selected trials were manually categorized according to indication(s), BT source, applied dose rate, primary sponsor type, location, protocol initiator and funding source. We analyzed trials across 8 available trial protocol elements registered within the database.ResultsIn total 245 clinical trials were identified, 147 with BT as primary investigated treatment modality and 98 that included BT as an optional treatment component or as part of the standard treatment. Academic centers were the most frequent protocol initiators in trials where BT was the primary investigational treatment modality (p < 0.01). High dose rate (HDR) BT was the most frequently investigated type of BT dose rate (46.3 %) followed by low dose rate (LDR) (42.0 %). Prostate was the most frequently investigated tumor entity in trials with BT as the primary treatment modality (40.1 %) followed by breast cancer (17.0 %). BT was rarely the primary investigated treatment modality for cervical cancer (6.8 %).ConclusionMost clinical trials using BT are predominantly in early phases, investigator-initiated and with low accrual numbers. Current investigational activities that include BT mainly focus on prostate and breast cancers. Important questions concerning the optimal usage of BT will not be answered in the near future.Electronic supplementary materialThe online version of this article (doi:10.1186/s13014-016-0624-8) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 70%

Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database

et al. 2016

View full text Add to dashboard Cite

show abstract

“…It also allows rapid relief in dysphagia due to high dose to the tumour bed. Brunner et al 16 delivered HDR brachytherapy sandwiched with EBRT with the hypothesis that a better dose coverage is expected due to decreased tumour thickness.…”

Section: Ilrtresultsmentioning

confidence: 99%

Brachytherapy for Oesophageal Carcinoma: A Comprehensive Review of Literature and Techniques

et al. 2021

View full text Add to dashboard Cite

Introduction: Oesophageal carcinoma is one of the fatal cancers mainly because of its rapid spread and poor prognosis. Treatment modalities involves a multimodality approach, including surgery, radiation therapy and chemotherapy. Radiation therapy includes brachytherapy in the form of intraluminal radiation therapy. Brachytherapy permits delivery of high tumouricidal doses to superficial cancerous growth of the oesophagus while delivering much lower doses to the surrounding tissue. It is mostly given in combination with external beam radiation in patients with poor performance scores not likely to tolerate an aggressive chemoradiation regimen or as a boost to concurrent chemoradiotherapy. It is very effective in terms of local tumour control as well as in relieving symptoms in advanced/recurrent disease. Intraoperative brachytherapy and seed brachytherapy have also been tried to address the nodal disease. Methods: We undertook a review of the available literature and techniques developed in the past three decades to emphasise the role of brachytherapy in curative or palliative settings in the treatment of oesophageal carcinoma. Conclusion: Oesophageal brachytherapy will remain a tangible treatment of oesophageal cancer, although it is less commonly used due to high expertise requirement, lack of established evidence, risk of life-threatening complications and lack of interest in brachytherapy. It offers quick and useful palliation for a prolonged period, along with good quality of life and superior dosimetry. Use of novel applicators may allow dose escalation and lower toxicity. Seed brachytherapy is also emerging as a promising option in nodal recurrences.

show abstract

Clinical Applications of High-Dose-Rate Brachytherapy

Nag

Scruggs

2011

Medical Radiology

View full text Add to dashboard Cite

Esophageal Cancer

Abstract: Survival was excellent especially for patients without nodal disease in this dose-intensified schedule with acceptable tolerability.

Cited by 19 publications

References 27 publications

Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database

Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database

Brachytherapy for Oesophageal Carcinoma: A Comprehensive Review of Literature and Techniques

Clinical Applications of High-Dose-Rate Brachytherapy

Contact Info

Product

Resources

About